Generic Name and Formulations:
Etomidate 2mg/mL; soln for IV inj.
Indications for AMIDATE:
For the induction of general anesthesia. For the supplementation of subpotent anesthetic agents (eg, nitrous oxide in oxygen) during maintenance of anesthesia for short operative procedures (eg, dilation and curettage, cervical conization).
Adults and Children:
<10yrs: not recommended. Induction: Give by IV inj over 30–60 seconds. ≥10yrs: Individualize. Usual range: 0.2–0.6mg/kg. Usual dose: 0.3mg/kg. Elderly: may need to reduce dose. Supplementation: smaller increments may be given.
To be administered only by those experienced in general anesthesia. May reduce plasma cortisol and aldosterone concentrations; consider exogenous replacement in patients undergoing severe stress. Pediatric neurotoxicity risk with repeated or prolonged use. Renal impairment. Elderly (may induce cardiac depression). Labor & delivery: not recommended. Pregnancy (Cat.C). Nursing mothers.
Concomitant IV fentanyl and other neuroactive drugs; may need to adjust etomidate dose.
Transient venous pain on inj, transient skeletal muscle movements including myoclonus, hyper- or hypoventilation, apnea, laryngospasm, hiccup, snoring, hyper- or hypotension, tachycardia, arrhythmias, post-op nausea/vomiting.
Vial—10mL, 20mL; Ampul—10mL, 20mL; Abboject syringe—20mL
Endocrinology Advisor Articles
- Soluble Klotho Levels Predictive of Kidney Failure in Type 2 Diabetes
- HbA1c Levels Predictive of Liraglutide Treatment Response in T2D
- Clinicians May Be Overtreating Older Patients With Diabetes
- Comorbid and Pharmacologic Factors Increase Risk for Gastrointestinal Disorders in Diabetes
- ADA Updates Guidelines for Cardiovascular Risk Management in Diabetes
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Hormonal Contraceptives May Adversely Affect Psychological Health in Adolescent Girls
- Obesity Can Negatively Effect Liver in Children as Young as 8
- Recommendations Developed on Gender Equity in Medicine
- Intensive Lifestyle Interventions Cut Long-Term Disability in Type 2 Diabetes